Forget Moderna: This Biotech Juggernaut Is Rising Fast
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesA biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Steve Wozniak reflects on the motivations behind founding Apple, revealing a desire for invention over cash and a $50...
If SpaceX ever hits the public markets, the big question isn’t rocket tech or Starlink alone. It’s whether the compan...
Memory-chip giants Micron and SK Hynix push into the $1 trillion market-cap club, signaling renewed confidence in AI-...
Samsung units are set to acquire a $408 million stake in Dunamu, the operator of Upbit, signaling a major push by dom...
A new HMDA analysis reveals a wide gap between DPA-eligible borrowers and actual users, underscoring outreach and acc...
Nvidia CEO Jensen Huang’s remark on AI-proof degrees has sparked a broader debate about job security in an era of rap...
Vertex Pharmaceuticals is being pitched as a durable cash-flow king for patient investors. This piece analyzes the ca...
Netflix and Spotify face off for retirement portfolios as mid-2026 conditions test growth, margins, and free cash flo...
DraftKings is under renewed scrutiny as it rolls out Predictions and posts a mixed Q1 2026. Our price prediction: dkn...
Bitmine filed for a public offering of 3 million shares of a 9.50% perpetual preferred stock to accelerate ETH holdin...
A sharp rally in the First Trust NASDAQ Cybersecurity ETF (CIBR) outperformed the S&P 500 in early June 2026, sparkin...